Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [65]
- Comments [0]
- Validations
- Western blot [2]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-13672 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- ErbB2 (HER-2) Monoclonal Antibody (3B5), Biotin
- Antibody type
- Monoclonal
- Antigen
- Synthetic peptide
- Description
- MA5-13672 targets HER-2 in IHC, IP, and WB applications and shows reactivity with Human, mouse, Non-human primate, and Rat samples.
- Conjugate
- Biotin
- Antibody clone number
- 3B5
- Concentration
- 0.2 mg/mL
Submitted references Impedance spectroscopy assisted by magnetic nanoparticles as a potential biosensor principle for breast cancer cells in suspension.
A cell-based screening system for influenza A viral RNA transcription/replication inhibitors.
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases.
EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression.
Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.
HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.
Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes.
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Protein expression profiling of primary mammary epithelial cells derived from MMTV-neu mice revealed that HER2/NEU-driven changes in protein expression are functionally clustered.
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice.
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
Loss of annexin A1 expression in breast cancer progression.
A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents.
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
Primary neuroendocrine carcinoma of the breast: a case report.
Primary neuroendocrine carcinoma of the breast: a case report.
Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells.
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
ErbB4 regulates fetal surfactant phospholipid synthesis in primary fetal rat type II cells.
Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis.
[An analysis of genetic transmission in a father and son with osteosarcoma].
MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC).
Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy.
Effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology.
ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells.
Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation.
Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells.
Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer.
Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.
Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition.
HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors.
Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope.
Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope.
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Profiling receptor tyrosine kinase activation by using Ab microarrays.
Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome.
Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome.
Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Silva JG, Cárdenas RA, Quiróz AR, Sánchez V, Lozano LM, Pérez NM, López J, Villanueva C, González CA
Physiological measurement 2014 Jun;35(6):931-41
Physiological measurement 2014 Jun;35(6):931-41
A cell-based screening system for influenza A viral RNA transcription/replication inhibitors.
Ozawa M, Shimojima M, Goto H, Watanabe S, Hatta Y, Kiso M, Furuta Y, Horimoto T, Peters NR, Hoffmann FM, Kawaoka Y
Scientific reports 2013;3:1106
Scientific reports 2013;3:1106
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2013 Jun;54(6):936-43
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2013 Jun;54(6):936-43
Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases.
Yigit S, Pehlivan FS, Evcim G, Etit D
Pathology, research and practice 2012 Mar 15;208(3):147-50
Pathology, research and practice 2012 Mar 15;208(3):147-50
EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
Cortés MA, Cariaga-Martinez AE, Lobo MV, Martín Orozco RM, Motiño O, Rodríguez-Ubreva FJ, Angulo J, López-Ruiz P, Colás B
Carcinogenesis 2012 Jun;33(6):1169-77
Carcinogenesis 2012 Jun;33(6):1169-77
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
Hechtman JF, Polydorides AD
Archives of pathology & laboratory medicine 2012 Jun;136(6):691-7
Archives of pathology & laboratory medicine 2012 Jun;136(6):691-7
Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
El-Gendi SM, Mostafa MF, El-Gendi AM
Pathology oncology research : POR 2012 Apr;18(2):459-69
Pathology oncology research : POR 2012 Apr;18(2):459-69
Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression.
de Assis S, Warri A, Benitez C, Helferich W, Hilakivi-Clarke L
Cancer prevention research (Philadelphia, Pa.) 2011 Sep;4(9):1436-48
Cancer prevention research (Philadelphia, Pa.) 2011 Sep;4(9):1436-48
Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
Abdelzaher E, El-Gendi SM, Yehya A, Gowil AG
British journal of neurosurgery 2011 Dec;25(6):707-13
British journal of neurosurgery 2011 Dec;25(6):707-13
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J
Breast cancer research : BCR 2011 Apr 15;13(2):R44
Breast cancer research : BCR 2011 Apr 15;13(2):R44
Low Level of Her-2 Locus Amplification by Fluorescent In Situ Hybridization Does Not Correlate with Her-2 Protein Overexpression by Immunohistochemistry in Barrett's Esophagus.
Rygiel AM, Milano F, Ten Kate FJ, Bergman JJ, Krishnadath KK
Journal of oncology 2010;2010:382582
Journal of oncology 2010;2010:382582
HER-2 signaling, acquisition of growth factor independence, and regulation of biological networks associated with cell transformation.
Bollig-Fischer A, Dziubinski M, Boyer A, Haddad R, Giroux CN, Ethier SP
Cancer research 2010 Oct 15;70(20):7862-73
Cancer research 2010 Oct 15;70(20):7862-73
Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes.
Hoa N, Ge L, Kuznetsov Y, McPherson A, Cornforth AN, Pham JT, Myers MP, Ahmed N, Salsman VS, Lamb LS Jr, Bowersock JE, Hu Y, Zhou YH, Jadus MR
Journal of immunology (Baltimore, Md. : 1950) 2010 Oct 15;185(8):4793-803
Journal of immunology (Baltimore, Md. : 1950) 2010 Oct 15;185(8):4793-803
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R
Journal of translational medicine 2010 Jun 7;8:53
Journal of translational medicine 2010 Jun 7;8:53
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A
Cancer 2010 Jul 15;116(14):3330-7
Cancer 2010 Jul 15;116(14):3330-7
Protein expression profiling of primary mammary epithelial cells derived from MMTV-neu mice revealed that HER2/NEU-driven changes in protein expression are functionally clustered.
Park S, Lee KM, Ju JH, Kim J, Noh DY, Lee T, Shin I
IUBMB life 2010 Jan;62(1):41-50
IUBMB life 2010 Jan;62(1):41-50
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
Chandarlapaty S, Scaltriti M, Angelini P, Ye Q, Guzman M, Hudis CA, Norton L, Solit DB, Arribas J, Baselga J, Rosen N
Oncogene 2010 Jan 21;29(3):325-34
Oncogene 2010 Jan 21;29(3):325-34
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA
American journal of clinical pathology 2010 Aug;134(2):303-11
American journal of clinical pathology 2010 Aug;134(2):303-11
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
Misirlioglu D, Nak D, Ozyigit MO, Nak Y, Akkoc A
Journal of feline medicine and surgery 2009 Oct;11(10):885-8
Journal of feline medicine and surgery 2009 Oct;11(10):885-8
Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice.
Strumane K, Rygiel T, van der Valk M, Collard JG
Journal of cancer research and clinical oncology 2009 Jan;135(1):69-80
Journal of cancer research and clinical oncology 2009 Jan;135(1):69-80
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
Hakim AA, Barry CP, Barnes HJ, Anderson KE, Petitte J, Whitaker R, Lancaster JM, Wenham RM, Carver DK, Turbov J, Berchuck A, Kopelovich L, Rodriguez GC
Cancer prevention research (Philadelphia, Pa.) 2009 Feb;2(2):114-21
Cancer prevention research (Philadelphia, Pa.) 2009 Feb;2(2):114-21
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blättler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX
Cancer research 2008 Nov 15;68(22):9280-90
Cancer research 2008 Nov 15;68(22):9280-90
Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S, Zhu Z, Li L, Chang L, Li W, Cheng L, Teng M, Liu J
Proteins 2008 Feb 15;70(3):938-49
Proteins 2008 Feb 15;70(3):938-49
Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
Katsumi Y, Kuwahara Y, Tamura S, Kikuchi K, Otabe O, Tsuchiya K, Iehara T, Kuroda H, Hosoi H, Sugimoto T
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Feb 15;14(4):1192-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Feb 15;14(4):1192-9
Loss of annexin A1 expression in breast cancer progression.
Cao Y, Li Y, Edelweiss M, Arun B, Rosen D, Resetkova E, Wu Y, Liu J, Sahin A, Albarracin CT
Applied immunohistochemistry & molecular morphology : AIMM 2008 Dec;16(6):530-4
Applied immunohistochemistry & molecular morphology : AIMM 2008 Dec;16(6):530-4
A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents.
Piechocki MP
BMC cancer 2008 Apr 24;8:119
BMC cancer 2008 Apr 24;8:119
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ
Breast cancer research : BCR 2007;9(5):R65
Breast cancer research : BCR 2007;9(5):R65
Primary neuroendocrine carcinoma of the breast: a case report.
Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E
Tumori 2007 Sep-Oct;93(5):496-8
Tumori 2007 Sep-Oct;93(5):496-8
Primary neuroendocrine carcinoma of the breast: a case report.
Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E
Tumori 2007 Sep-Oct;93(5):496-8
Tumori 2007 Sep-Oct;93(5):496-8
Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells.
Half E, Sun Y, Sinicrope FA
Cancer letters 2007 Jun 28;251(2):237-46
Cancer letters 2007 Jun 28;251(2):237-46
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Jan 1;25(1):64-9
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Jan 1;25(1):64-9
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M
Cancer 2007 Feb 1;109(3):496-501
Cancer 2007 Feb 1;109(3):496-501
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Martín-Orozco RM, Almaraz-Pro C, Rodríguez-Ubreva FJ, Cortés MA, Ropero S, Colomer R, López-Ruiz P, Colás B
Neoplasia (New York, N.Y.) 2007 Aug;9(8):614-24
Neoplasia (New York, N.Y.) 2007 Aug;9(8):614-24
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Martín-Orozco RM, Almaraz-Pro C, Rodríguez-Ubreva FJ, Cortés MA, Ropero S, Colomer R, López-Ruiz P, Colás B
Neoplasia (New York, N.Y.) 2007 Aug;9(8):614-24
Neoplasia (New York, N.Y.) 2007 Aug;9(8):614-24
ErbB4 regulates fetal surfactant phospholipid synthesis in primary fetal rat type II cells.
Zscheppang K, Liu W, Volpe MV, Nielsen HC, Dammann CE
American journal of physiology. Lung cellular and molecular physiology 2007 Aug;293(2):L429-35
American journal of physiology. Lung cellular and molecular physiology 2007 Aug;293(2):L429-35
Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis.
Vairaktaris E, Moulavassili P, Loukeri S, Spyridonidou S, Yapijakis C, Vassiliou S, Nkenke E, Vylliotis A, Papakosta V, Lazaris A, Patsouris E
Journal of musculoskeletal & neuronal interactions 2007 Apr-Jun;7(2):185-90
Journal of musculoskeletal & neuronal interactions 2007 Apr-Jun;7(2):185-90
[An analysis of genetic transmission in a father and son with osteosarcoma].
Tokatli F, Alas RC, Altaner S, Pala F, Uygun K, Uzal C, Yalniz E
Acta orthopaedica et traumatologica turcica 2006;40(5):407-10
Acta orthopaedica et traumatologica turcica 2006;40(5):407-10
MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC).
Karg A, Dinç ZA, Başok O, Uçvet A
Pathology, research and practice 2006;202(8):577-83
Pathology, research and practice 2006;202(8):577-83
Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy.
Qu S, Rinehart C, Wu HH, Wang SE, Carter B, Xin H, Kotlikoff M, Arteaga CL
Genesis (New York, N.Y. : 2000) 2006 Oct;44(10):477-86
Genesis (New York, N.Y. : 2000) 2006 Oct;44(10):477-86
Effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology.
Shyamala G, Chou YC, Cardiff RD, Vargis E
Cancer research 2006 Nov 1;66(21):10391-8
Cancer research 2006 Nov 1;66(21):10391-8
ErbB receptor dimerization, localization, and co-localization in mouse lung type II epithelial cells.
Zscheppang K, Korenbaum E, Bueter W, Ramadurai SM, Nielsen HC, Dammann CE
Pediatric pulmonology 2006 Dec;41(12):1205-12
Pediatric pulmonology 2006 Dec;41(12):1205-12
Constitutive neuregulin-1/ErbB signaling contributes to human vestibular schwannoma proliferation.
Hansen MR, Roehm PC, Chatterjee P, Green SH
Glia 2006 Apr 15;53(6):593-600
Glia 2006 Apr 15;53(6):593-600
Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells.
Stewart LV, Lyles B, Lin MF, Weigel NL
The Journal of steroid biochemistry and molecular biology 2005 Oct;97(1-2):37-46
The Journal of steroid biochemistry and molecular biology 2005 Oct;97(1-2):37-46
Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer.
Khalili P, Arakelian A, Chen G, Singh G, Rabbani SA
Oncogene 2005 Oct 6;24(44):6657-66
Oncogene 2005 Oct 6;24(44):6657-66
Expression, location, and interactions of ErbB2 and its intramembrane ligand Muc4 (sialomucin complex) in rat mammary gland during pregnancy.
Price-Schiavi SA, Andrechek E, Idris N, Li P, Rong M, Zhang J, Carothers Carraway CA, Muller WJ, Carraway KL
Journal of cellular physiology 2005 Apr;203(1):44-53
Journal of cellular physiology 2005 Apr;203(1):44-53
Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition.
Lenferink AE, Magoon J, Cantin C, O'Connor-McCourt MD
Breast cancer research : BCR 2004;6(5):R514-30
Breast cancer research : BCR 2004;6(5):R514-30
HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors.
Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA
International journal of cancer 2004 Feb 10;108(4):540-8
International journal of cancer 2004 Feb 10;108(4):540-8
Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
Zinser GM, Welsh J
Carcinogenesis 2004 Dec;25(12):2361-72
Carcinogenesis 2004 Dec;25(12):2361-72
Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A
Cancer 2003 Sep 1;98(5):1055-60
Cancer 2003 Sep 1;98(5):1055-60
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, McConkey DJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Mar;9(3):955-60
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Mar;9(3):955-60
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC Jr, Kudelka AP, Kavanagh JJ, Giovanella BC
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Feb;9(2):845-52
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Feb;9(2):845-52
Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope.
Lucchese A, Stevanovic S, Sinha AA, Mittelman A, Kanduc D
Peptides 2003 Feb;24(2):193-7
Peptides 2003 Feb;24(2):193-7
Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope.
Lucchese A, Stevanovic S, Sinha AA, Mittelman A, Kanduc D
Peptides 2003 Feb;24(2):193-7
Peptides 2003 Feb;24(2):193-7
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Simpson RH, Prasad AR, Lewis JE, Skálová A, David L
The American journal of surgical pathology 2003 Aug;27(8):1070-9
The American journal of surgical pathology 2003 Aug;27(8):1070-9
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
Simpson RH, Prasad AR, Lewis JE, Skálová A, David L
The American journal of surgical pathology 2003 Aug;27(8):1070-9
The American journal of surgical pathology 2003 Aug;27(8):1070-9
Profiling receptor tyrosine kinase activation by using Ab microarrays.
Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK
Proceedings of the National Academy of Sciences of the United States of America 2003 Aug 5;100(16):9330-5
Proceedings of the National Academy of Sciences of the United States of America 2003 Aug 5;100(16):9330-5
Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.
Kremser R, Obrist P, Spizzo G, Erler H, Kendler D, Kemmler G, Mikuz G, Ensinger C
Virchows Archiv : an international journal of pathology 2003 Apr;442(4):322-8
Virchows Archiv : an international journal of pathology 2003 Apr;442(4):322-8
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 15;170(8):4242-53
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 15;170(8):4242-53
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PT
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 15;170(8):4242-53
Journal of immunology (Baltimore, Md. : 1950) 2003 Apr 15;170(8):4242-53
Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
Van Eeden S, Quaedvlieg PF, Taal BG, Offerhaus GJ, Lamers CB, Van Velthuysen ML
Human pathology 2002 Nov;33(11):1126-32
Human pathology 2002 Nov;33(11):1126-32
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA
Cancer research 2002 Mar 15;62(6):1676-81
Cancer research 2002 Mar 15;62(6):1676-81
Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome.
Mittelman A, Lucchese A, Sinha AA, Kanduc D
International journal of cancer 2002 Apr 10;98(5):741-7
International journal of cancer 2002 Apr 10;98(5):741-7
Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome.
Mittelman A, Lucchese A, Sinha AA, Kanduc D
International journal of cancer 2002 Apr 10;98(5):741-7
International journal of cancer 2002 Apr 10;98(5):741-7
Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
Murillo H, Schmidt LJ, Tindall DJ
Cancer research 2001 Oct 15;61(20):7408-12
Cancer research 2001 Oct 15;61(20):7408-12
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Moasser MM, Basso A, Averbuch SD, Rosen N
Cancer research 2001 Oct 1;61(19):7184-8
Cancer research 2001 Oct 1;61(19):7184-8
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot of HER-2 using HER-2 Monoclonal Antibody (Product # MA5-13672) on SKBR3 Cells and MAD109 Cells.
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on membrane enriched extracts (30 µg lysate) of SK-BR-3 (1) and MDA-MB-231 (2). The blots were probed with Anti-ErbB2 Mouse Monoclonal Antibody (Product # MA5-13672, 1 µg/mL dilution) and detected by chemiluminescence using Streptavidin-HRP (Product # N200, 1:10,000 dilution). A 185 kDa band corresponding to ErbB2 was observed in SK-BR-3 but not in MDA-MB-231, which is a negative control for ErbB2. Known quantity of protein samples were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX), XCell SureLock™ Electrophoresis System (Product # EI0002) and Novex® Sharp Pre-Stained Protein Standard (Product # LC5800). Resolved proteins were then transferred onto a nitrocellulose membrane using the wet transfer system. The membrane was probed with the relevant primary antibody following blocking with 5 % skimmed milk. Chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).
- Conjugate
- Biotin
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of HER-2 using HER-2 Monoclonal Antibody (Product # MA5-13672) on denatured Human SKBR3 Cells.
- Conjugate
- Biotin
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunoprecipitation of HER-2 using HER-2 Monoclonal Antibody (Product # MA5-13672) on Native Human SKBR3 Cells.
- Conjugate
- Biotin
